Ocular Therapeutix, Inc.
OCUL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.59 | -0.92 | 3.19 | 1.38 |
| FCF Yield | -10.06% | -21.44% | -29.31% | -12.54% |
| EV / EBITDA | -5.88 | -3.67 | -2.88 | 168.29 |
| Quality | ||||
| ROIC | -41.05% | -37.66% | -65.82% | -43.31% |
| Gross Margin | 91.17% | 90.96% | 91.18% | 89.88% |
| Cash Conversion Ratio | 0.70 | 0.87 | 0.84 | 10.00 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.36% | 10.33% | 43.56% | 3,517,417.62% |
| Free Cash Flow Growth | -78.15% | -20.54% | 5.13% | -22.70% |
| Safety | ||||
| Net Debt / EBITDA | 1.80 | 1.69 | 0.61 | -41.43 |
| Interest Coverage | -12.65 | -7.27 | -11.20 | -11.70 |
| Efficiency | ||||
| Inventory Turnover | 1.85 | 2.29 | 2.30 | 3.52 |
| Cash Conversion Cycle | 111.82 | 19.46 | -102.01 | -99.61 |